Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suprachoroidal Triamcinolone Acetonide in Treatment-Naïve Center-Involving Diabetic Macular Edema
NCT07870226Phase 2Not yet recruiting
- Sponsor
- Khyber Girls Medical College
- Start
- Sep 2026
- Primary completion
- Jun 2027
01
Overview
Phase 2, open-label, single-arm trial of triamcinolone in diabetic macular edema (DME), sponsored by Khyber Girls Medical College. Primary endpoints: Best-Corrected Visual Acuity at 6 months and Visual Acuity at 6 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
triamcinolone
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT07870226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07870226.